Dna methylation in inflammatory disease
AssigneeIndiana University Research and Technology Corporation
InventorRaghavendra G. MIRMIRA
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA and chromatin target of PRMT1 (CHTOP).
Claims14
A method for determining the methylated state of human preproinsulin (INS) and human chromatin target of PRMT1 (CHTOP) DNA in a patient's cell free circulating DNA, said method comprising the steps of
- subjecting a DNA sample isolated from a plasma or serum sample recovered from said patient to a bisulfite reaction;
- and
- measuring the methylation state of both preproinsulin and chromatin target of PRMT1 (CHTOP) DNA present in said bisulfite treated DNA sample.
A kit for measuring the methylated state of preproinsulin and CHTOP said kit comprising a nucleic acid molecule selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 7, SEQ ID NO:
- 8;
- SEQ ID NO:
- 12 and SEQ ID NO:
- 13.
A method for determining inflammation in a subject suspected of having inflammation, the method comprising:
- amplifying methylated preproinsulin DNA in a sample obtained from the subject suspected of having inflammation;
- amplifying unmethylated preproinsulin DNA in a sample obtained from the subject suspected of having inflammation;
- comparing the concentration of methylated preproinsulin DNA and unmethylated preproinsulin DNA in the sample with the concentration of methylated preproinsulin DNA and unmethylated preproinsulin DNA in a control;
- and
- determining that the subject has inflammation when the concentration of methylated preproinsulin DNA in the sample is greater than the concentration of methylated preproinsulin DNA in the control.
Dependencies are inferred from the claim text.